Sentien Biotechnologies

About:

Sentien is a developer of new blood conditioning therapies designed to restore balance to the immune system of critically ill patients.

Website: http://www.sentienbiotech.com/

Twitter/X: sentienbiotech

Top Investors: Boehringer Ingelheim Venture Fund, Mass Medical Angels, BioInnovation, MBLVC, Chiesi Ventures

Description:

Sentien Biotechnologies is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach has been proven to significantly enhance exposure and extend therapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, their flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion. Sentien Biotechnologies was established in 2008 and is headquartered in Lexington, Massachusetts, United States.